Nothing Special   »   [go: up one dir, main page]

Wang et al., 2022 - Google Patents

Implications of NKG2A in immunity and immune-mediated diseases

Wang et al., 2022

View HTML
Document ID
1761248291780405082
Author
Wang X
Xiong H
Ning Z
Publication year
Publication venue
Frontiers in immunology

External Links

Snippet

In recent studies, NKG2A is revealed to be a key immune checkpoint for both natural killer (NK) cells and CD8+ T cells. It form heterodimer receptors with CD94, and targets the peptide-presenting human leukocyte antigen-E (HLA-E) molecules. Upon crosslinking …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Similar Documents

Publication Publication Date Title
Wang et al. Implications of NKG2A in immunity and immune-mediated diseases
Ning et al. Roles of BTLA in immunity and immune disorders
Mizuno et al. PD-1 primarily targets TCR signal in the inhibition of functional T cell activation
Maruhashi et al. LAG-3: from molecular functions to clinical applications
Sun et al. The rise of NK cell checkpoints as promising therapeutic targets in cancer immunotherapy
Khan et al. NK cell-based immune checkpoint inhibition
US20240174747A1 (en) T cell regulation
Qin et al. Insights into the molecular mechanisms of T follicular helper-mediated immunity and pathology
Zhou et al. Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8+ T cells
Park et al. TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer
Mercadante et al. Breaking free of control: how conventional T cells overcome regulatory T cell suppression
Lu et al. SLAM receptors foster iNKT cell development by reducing TCR signal strength after positive selection
Pillemer et al. Deficient SOCS3 expression in CD4+ CD25+ FoxP3+ regulatory T cells and SOCS3‐mediated suppression of Treg function
Abdallah et al. Leukocyte immunoglobulin-like receptors in regulating the immune response in infectious diseases: A window of opportunity to pathogen persistence and a sound target in therapeutics
O’Brien et al. Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production
Villa-Álvarez et al. Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic leukemia
JP2019528699A (en) Immune cell compositions and methods of use for treating viruses and other infections
Braud et al. LLT1-CD161 interaction in cancer: promises and challenges
Guram et al. A threshold model for T-cell activation in the era of checkpoint blockade immunotherapy
Fujiwara et al. Cbl-b deficiency mediates resistance to programmed death-ligand 1/programmed death-1 regulation
Zhu et al. Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer
Gertel et al. Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases
Borges et al. Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms
Redondo-García et al. Human leukocyte immunoglobulin-like receptors in health and disease
Yang et al. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy